Doctor Evidence’s 2012 success can be attributed both to the expansion of existing projects as well as the start of new initiatives with a varied list of clients, including academic groups, provider networks, managed care organizations, and nine of the top ten medical manufacturers (life science and device).

Among 2012 achievements was the continued collaboration between Doctor Evidence and distinguished healthcare organizations—such as Kaiser Permanente—on the development of the Guidelines Consortium, which enlists the capabilities of the Doctor Evidence product suite to create and share evidence-backed guidelines with colleagues all over the world.  A wider rollout is planned for Q3 2013, with several large and prominent healthcare transformation systems joining the Doctor Evidence Guideline Consortium Network. The Guideline Consortium Network will be featured to a global audience of stakeholders at the upcoming Guidelines International Network (GIN) Conference in San Francisco, California in August 2013.

The past year also saw the launch and refinement of Doctor Evidence’s groundbreaking DOC™ Label product, which enables clients in the regulatory affairs and labeling departments of institutions to save, search, and compare over 23,000 prescription drug labels and label versions from the FDA in minutes rather than the hours or even days a more traditional search would require.

About Doctor Evidence, LLC

Doctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical and business decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from published clinical studies, FDA drug labels, and epidemiological databases to transform static data into reusable, dynamic relational databases. Our software platform empowers both public and private sector clients to identify the most relevant literature and conduct ready analyses with the highest level of transparency available for today’s evidence-based medicine methodological standards in the pursuit of reducing healthcare costs while increasing the quality of patient outcomes.

Doctor Evidence serves decision makers in two large addressable market segments: Medical Manufacturers and Healthcare Providers for the ultimate wellbeing of patients.  Doctor Evidence is helping to transform the healthcare ecosystem by identify the most efficacious and safe medical treatment on a comparative effectiveness basis, including related economic costs and total-cost-of-care analysis. 

Doctor Evidence, LLC is a specialty software platform and services company aimed to assist payers, providers and other members of the healthcare system to make and inform clinical and business decisions using the most relevant medical evidence.

Each individual clinical study may report hundreds or even thousands of individual data points, including values from baseline characteristics, primary endpoints and other outcomes, collected over a wide follow-up range. These data points are then digitized into interactive study summaries and made available online for additional operations such as meta-analysis and evidence table creation.

The Doctor Evidence system currently includes approximately 5,079,681 total data points from 7,188 digitized studies on a range of subjects including diabetes, rheumatoid arthritis and glaucoma. These studies report a total of 17,073 baseline characteristics and 21,329 unique outcomes, with totals increasing every day as new projects are completed.

About Doctor Evidence, LLC

Doctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical and business decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from published clinical studies, FDA drug labels, and epidemiological databases to transform static data into reusable, dynamic relational databases. Our software platform empowers both public and private sector clients to identify the most relevant literature and conduct ready analyses with the highest level of transparency available for today’s evidence-based medicine methodological standards in the pursuit of reducing healthcare costs while increasing the quality of patient outcomes.

Doctor Evidence serves decision makers in two large addressable market segments: Medical Manufacturers and Healthcare Providers for the ultimate wellbeing of patients.  Doctor Evidence is helping to transform the healthcare ecosystem by identify the most efficacious and safe medical treatment on a comparative effectiveness basis, including related economic costs and total-cost-of-care analysis. 

Key among the initiatives to be presented at GIN is the Guideline Consortium, an evidence-based member network of like-minded organizations for clinical guideline development. Members of the Guideline Consortium reduce duplication of resources and effort in guideline development by leveraging the collaborative capabilities of Doctor Evidence’s DOC™ product suite. Due to the infinite needs for topic review and finite resources of internal member resources, members benefit from a shared platform and standardized evidentiary quality assessments. The goal of the Guideline Consortium is to globalize the quality of the evidence review in a network while still providing flexibility to localize the recommendation by each member.

Founded in 2002, GIN is a global network of physicians, payers and other stakeholders in the development of evidence-based treatment guidelines. The GIN annual conference serves to unite members of this global network for communicating evidence-based care guidelines throughout the world.

For more information on GIN or the 2013 conference, see the conference website at www.gin2013.net.

About Doctor Evidence, LLC

Doctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical and business decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from published clinical studies, FDA drug labels, and epidemiological databases to transform static data into reusable, dynamic relational databases. Our software platform empowers both public and private sector clients to identify the most relevant literature and conduct ready analyses with the highest level of transparency available for today’s evidence-based medicine methodological standards in the pursuit of reducing healthcare costs while increasing the quality of patient outcomes.

Doctor Evidence serves decision makers in two large addressable market segments: Medical Manufacturers and Healthcare Providers for the ultimate wellbeing of patients.  Doctor Evidence is helping to transform the healthcare ecosystem by identify the most efficacious and safe medical treatment on a comparative effectiveness basis, including related economic costs and total-cost-of-care analysis. 

The re-launch offers a sleeker layout over the previous incarnation and explains Doctor Evidence’s product suite in terms of the company’s proprietary Digital Outcome Conversion (DOC™) approach to data collection and analysis. In the DOC™ approach, essential data are collected from published studies, epidemiological databases and other static sources and converted into a dynamic, web-based, comprehensive database platform.

This DOC™ approach applies across Doctor Evidence’s revamped and streamlined product line, which includes DOC™ Library for reference management, DOC™ Evidence for evidence organization and synthesis, and DOC™ NHANES. The site also includes two new additions to the DRE product line: DOC™ Create, and DOC™ Label. These DOC™ products, DRE’s guideline consortium, and consulting services make up the company’s current collection of offerings.

Other features of the updated website include a redesigned site menu, additional descriptive content for each of DRE’s products and services, and demonstration videos for various features of the DOC™ Library and DOC™ NHANES solutions. Additional video instruction for other DOC™ tools are in development and will be uploaded to the website upon their completion.

Visit our website at www.doctorevidence.com for more information.

About Doctor Evidence, LLC

Doctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical and business decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from published clinical studies, FDA drug labels, and epidemiological databases to transform static data into reusable, dynamic relational databases. Our software platform empowers both public and private sector clients to identify the most relevant literature and conduct ready analyses with the highest level of transparency available for today’s evidence-based medicine methodological standards in the pursuit of reducing healthcare costs while increasing the quality of patient outcomes.

Doctor Evidence serves decision makers in two large addressable market segments: Medical Manufacturers and Healthcare Providers for the ultimate wellbeing of patients.  Doctor Evidence is helping to transform the healthcare ecosystem by identify the most efficacious and safe medical treatment on a comparative effectiveness basis, including related economic costs and total-cost-of-care analysis. 

Doctor Evidence clients now include eight out of the top 10 pharmaceutical companies. The Company’s growth is part of an overall business strategy in pursuit of broad market adoptions and competitive sustainability of the Doctor Evidence cloud-based technologies and services. Productization of market-oriented segments of the Doctor Evidence platform architecture has led to greater reach and access into the market. Most notably, Doctor Evidence has galvanized its Payer Assisted Dialogue program to help manufacturers and payers communicate in a compliant oriented fashion to mutually determine the differentiation of a treatment in alignment with payer outcome interests.

“We are particularly pleased by the growth in our client base, as Doctor Evidence clients now include many of the leading manufacturer companies and distinguished evidence-based practice centers of excellence like Kaiser Permanente.  Kaiser Permanente uses Doctor Evidence’s cloud-based Virtual Collaborative Workspace platform to make its national care management guidelines,” said Doctor Evidence CEO Robert Battista. “We are happy with the consistent increase in revenues, but our greatest achievement this fiscal year has been the sustainable development of our relationship with Kaiser Permanente and other leading companies in the market.”

In 2011, Doctor Evidence nearly doubled the number of projects for Kaiser Permanente and engineered a collaborative workspace platform for use by the national guideline development team and further interaction with multiple departments inside of Kaiser to align evidence-based medicine practices. The work at Kaiser will be a model for development of other payer/provider and IDN networks to be a part of Doctor Evidence’s solutions offerings.  The companies plan to create a national guideline member network of care providers and payers that would like to contribute to and utilize a set of evidence-practice management guidelines.

In addition, Doctor Evidence has expanded its “NHANES Platform,” which enables browser-based access and rich analysis of the CDC’s National Health and Nutrition Examination Survey (NHANES). Sales of the NHANES Platform have increased by 76 percent since 2010, validating this product as a business-within-business type of offering.

The Evidence Engine enables browser-based access and in-depth analysis of the rich content of the CDC’sNational Health and Nutrition Examination Survey (NHANES). Although data from NHANES is available to the public, it is not provided in an easily searchable format, making it difficult and time-consuming to access. With the NHANES Evidence Engine, epidemiologists across organizations can avoid the painstaking task of mining survey data and can instead benefit from a centralized analytical tool.

“This is the only NHANES visual interface of its kind that follows the analytical guidelines of the Center for Disease Control,” said Edan Shalev, Chief Technology Officer of Doctor Evidence. “When seeking information from NHANES, we do all the hard work so that epidemiologists do not have to worry about weight variables, conforming data, complying with analytical guidelines, writing code, or calculating prevalence estimates.”

The NHANES Evidence Engine query tools display straightforward pull-screens and keyword searches. The system offers unlimited population breakdowns, survey cycle merges, prevalence comparisons, population estimates, variance estimates, forecasting models, and clear graphical statements. If desired, the raw data can be exported as well.

Now, with free trial access to the Evidence Engine’s Variable Browser, epidemiologists can see exactly what data is collected in the NHANES survey so to determine if their research questions can be answered and to see the breadth of information available. Please contact newsletter@doctorevidence.com.

Doctor Evidence was initially hired to catalogue and input this data into a searchable database. Later, the services expanded to include an advanced registration page, enhanced search features, international access, and periodic “user reports” to management.

“Before we discovered Doctor Evidence, LMA’s clinical research was poorly managed internally, with papers held on multiple servers and logged in Excel spreadsheets,” said Emma Donadieu, Product Manager. “Setting up the Doctor Evidence system has given us greater access to our data with the ability to search for key papers more effectively. Most importantly, it has given us the ability to share our data with customers.”

LMA has seen a huge spike in the number of visitors to the site. From 2010 to 2011, the company saw approximately a 100% increase in site visits and a 90% increase in unique users.

Features of the Doctor Evidence portal continue to evolve to meet growing LMA needs. Recent features include an editable “Top 10 Papers” report, a Chinese language portal, advanced reporting of user data reports and breakdown of papers viewed and printed by individual users.

“Given the success of the Chinese portal developed by Doctor Evidence, LMA is looking to expand the concept of the foreign language portal into other key markets,” Donadieu said.

Check out the full Case Study here: Case Study

Doctor Evidence’s powerful evidence solutions serve a variety of industries, such as life science, payor, academic, and pharmaceutical. As part of Doctor Evidence’s commitment to accuracy and client satisfaction, the latest version of the National Health and Nutrition Survey “Evidence Engine” now includes integration with SAS software. This integration will enhance confidence intervals, allow users to search content in an external browser, and provide export tools for query results. Doctor Evidence’s primary software solution, called the Evidence Portal, is an analytics system used to answer strategic clinical questions, inform formulary decision-makers, develop care management guidelines and help identify core efficacy, effectiveness and safety concerns. 

“Our products assist pharmaceutical companies maintain complete data transparency, provide evidence that supports products, and make comparative assessments for immediately responsive, CIA regulatory transparent communications to payers,” said Robert Battistia, CEO. “In an environment of increased regulation, our company is leading the way in the clinical evidence market. We are enthusiastic about the value our products will bring to top pharmaceutical companies.”

About Doctor Evidence

Doctor Evidence is the leader of digital software technologies companies which process clinical data and deliver information to industries within life science, healthcare, academia and government.  The Doctor Evidence database enables users to conduct meta analyses with the highest level of accuracy, relevance and efficiency in the evidence-based medicine market today.

Doctor Evidence is at the forefront of the healthcare comparative effectiveness and systematic review repository sector. Doctor Evidence is transforming the healthcare sector by providing a solution that reveals the “total cost-of-care” of any intervention in relation to its comparative efficacy and comprehensive care benefits.

As the US government strengthens regulatory enforcement efforts, manufacturers must enhance and modernize the systems and infrastructure that support medical communications compliance for clinical value statements. The critical challenges are to:

• Deliver compelling but fair balanced comparative effectiveness and safety data with the highest standards for regulatory compliance
• Avoid misuse of off-label information in scientific response and education programs

Medical Affairs departments as the scientific epicenter of market messaging are compelled to deliver fair balanced clinical content in an unbiased manner.   Just as the financial markets greatly benefited from an integrated general ledger cross functional system like the PeopleSoft financial platform, it would appear that medical affairs units can use a transparent and integrated approach to messaging data from published clinical studies—the gold standard for clinical differentiation.  Using data directly generated from full-text clinical articles that match the particular healthcare professional’s inquiry characteristics with the population characteristics, study purpose (“on” or “off” label) and endpoint values from published full-text articles, medical affairs departments would be instituting a fully compliant solution to the OIG’s guidance.  Key to such a solution is traceability and full transparency back to the source article to ensure regulatory compliance thereby reducing liability risk.  Additional requirements of a robust solution would be comprehensive management of authorization levels of each user to monitor only the evidence permissible under the user’s security clearance. The user interaction is tracked with every mouse click, which provides a closed loop audit pathway designed to simplify regulatory reporting requirements. The value provided to Medical Affairs from such a data driven evidence-based medicine approach would include:

• Decrease the response time of field medical inquiry requests exponentially through systematic
• Central data repository increases control of information and minimizes risk
• Decreases the costs of measuring compliance and the risk of fines related to un-authorized messaging
• Monitor system access and capture usage statistics for efficient regulatory reporting
• Increase the depth of clinical content available to health care professionals, customers and field managers
• Monitor evidence communications programs from design to dissemination

This concept of “Sending Efficient Responses with Valuable Evidence” with a centralized content repository from published studies is the ultimate protection for any organization that is looking to protect itself from regulatory infractions.

Traditionally, legacy content management systems have been the norm for storing, indexing and managing regulatory sanctioned pre-packaged clinical asset content.   In today’s high stakes and increasingly competitive environment, a new standard has evolved: delivering targeted data from the published literature to address clinical efficacy and safety differentiation. The centralized data platform approach allows an enterprise to utilize all relevant clinical evidence from published studies while monitoring user access to the content and managing permissions to regulate user compliance. By connecting users in every department to centralized, transparent and fair balanced data from published clinical studies, the system mitigates risks associated with the distribution of unsanctioned evidence.   In a world of joint and several punitive fines, such a system delivers the accountability necessary to stay competitive while increasing compliance.  The new paradigm of evidence identification, synthesis and analysis is based on an integrated software suite that incorporates all the data, definitions, and statistical information as reported from published studies into a highly structured central database that further complements the environmental payer data trends and emerging appetite for clinical analytics.

For more on the subject, please see Gary Cokins at SAS in his interesting analysis: Closing the Intelligence Gap.

The GRADE methodology gives researchers a powerful, standardized method for evaluating evidence and making recommendations.  The Doctor Evidence technology organizes and normalizes clinical data, making it easier to  apply the GRADE methodology.  The collaboration will yield a technology-enabled approach to every phase of systematic review development: reviewing literature, analyzing clinical data, and evaluating the quality of the evidence to provide recommendations and key findings.

“The integration of GRADE into the Doctor Evidence platform further enhances the value and utility of the methodology for healthcare researchers and decision makers,” says Dr. Holger Schunemann, Chair of McMaster’s renowned Department of Clinical Epidemiology and Biostatistics.  “We expect that this partnership will accelerate the adoption of GRADE throughout healthcare and make GRADE more accessible to organizations outside of academia.”

“This partnership will support our mission to offer a comprehensive solution for evidence evaluation,” comments Robert Battista, CEO of Doctor Evidence. “Our product is perfectly designed to leverage the benefits of the GRADE methodology, while reducing the work effort our clients face in deploying new methods for evidence synthesis.  We are excited to offer our clients this highly respected rubric for rating the quality of the body of evidence, which will lead to more precise clinical analysis and strengthen confidence in decision making.”